JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation is allowed to use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website for educational purpose only. Bodily introduction of any kind into humans and animals is strictly forbidden by law. This product should only be handled by licenced qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused as a drug, food and cosmetic.
FREE Shipping for orders over $200
For this product you will need: BACTERIOSTATIC WATER For reconstitution.
Tirzepatide is a 39 amino acid synthetic analogue of gastro-inhibitory polypeptide (GIP) which is designed to stimulate both GIP and GLP-1 (glucagon-like peptide) receptor pathways. These peptide hormones are part of intricate endocrine signal transduction and cell-cell communication pathways.
Tirzepatide has been used as a dual-acting peptide analogue to study receptor engagement, second-messenger modulation and signalling dynamics in both pancreatic and peripheral tissue models. Its interactions on the molecular level give evidence for stability of the peptide, receptor selectivity and pathway cross talk under defined experimental conditions.
Tirzepatide was originated by Eli Lilly, and patent applications date to 2016. Its architecture and signalling capacity have generated interest in laboratory research for peptide engineering and metabolic pathway interrogation. Our tirzepatide for sale can only be used for educational and scientific purposes by trained professionals.
From Pubchem
Â
Synonyms: Mounjaro, LY3298176 Molecular Weight: 4813 g/molMolecular Formula: C225H348N48O68 CAS number: 2023788-19-2 PubChem CID: 163285897
Tirzepatide has been examined for its dual activation of GIP and GLP-1 receptor systems, providing a model for investigating peptide–receptor interactions and intracellular signalling cascades. Studies in structured experimental frameworks, including the SURPASS series, have focused on receptor engagement, second-messenger modulation, and pathway integration under controlled laboratory conditions [1].
Additional investigations explored combinatorial interactions of tirzepatide with other peptide analogues to assess mechanistic behaviour, receptor selectivity, and signalling dynamics in varied experimental setups [2].
Further experimental frameworks, such as the SURPASS 6 protocols, have emphasized comparative evaluation of molecular signalling properties, pathway modulation, and analytical characterizations of tirzepatide in relation to reference compounds, without implying clinical efficacy or human outcomes [3].
Investigations within the SURPASS 1–5 experimental frameworks have explored tirzepatide’s dual GIP/GLP-1 receptor activity, providing a basis for examining peptide -receptor engagement, intracellular signal modulation, and pathway interactions under controlled laboratory conditions [4].
Additional experimental frameworks, including SURAMOUNT 1, have focused on systematic evaluation of tirzepatide’s receptor selectivity, signalling dynamics, and mechanistic behaviour across varied analogue concentrations and controlled administration schedules [5].
SURAMOUNT 2 protocols have further investigated molecular and cellular signalling characteristics, comparative receptor activity, and pathway integration of tirzepatide under experimental conditions, without implying clinical outcomes, human efficacy, or therapeutic benefit [6].
Experimental studies have examined tirzepatide’s influence on cardiovascular-related signalling pathways. In one model, tirzepatide modulated inflammatory and stress-response markers, affecting cardiomyocyte signalling via TLR4/NF-κB/NLRP3 pathway interactions [7].
Further analyses of structured SURPASS frameworks investigated tirzepatide-associated modulation of vascular and lipid-related signalling cascades under controlled laboratory conditions [8, 9]. These studies focused on mechanistic behaviour, intracellular responses, and pathway integration rather than human or clinical outcomes.
Tirzepatide continues to be investigated for its dual GIP/GLP-1 receptor activity and related signalling mechanisms. Additional experimental frameworks, including SURAMOUNT protocols, focus on mechanistic exploration, pathway modulation, and receptor-mediated interactions under controlled laboratory conditions. Tirzepatide for sale available at Element CRP is supplied exclusively for research, analytical, and educational purposes and is restricted to qualified researchers. Only buy Tirzepatide if you are a qualified researcher.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Element CRP is a chemical supplier. Element CRP is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Element CRP is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
